Sign in to view content

Results From Part 1 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for Geographic Atrophy: Glyco-immunologic Modulation of Macrophage Activity

Rishi P. Singh, MD

Video
Published 2024

Related

Episode 196: Dr. Sharon Fekrat on vitreretinal fellow education, alpha-melanocyte stimulating hormone and more
Jayanth Sridhar, MD
Member Podcasts
2019
Visual Acuity and Reading With One Eye Versus Both Eyes Open in Geographic Atrophy and Associations With Patient-Reported Vision-Related Function
Jun Kong, MD, PhD
On Demand Cases, Courses, and Papers
2021
Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates Continued Reduction in Geographic Atrophy Growth: 18-Month Results From GATHER1 Clinical Trial
Jason Hsu, MD
Annual Meeting Talks
2021

Category: AMD-Non-Neovascular

See more